The three phase I/II clinical trials use EGFR CAR-T cells expressing antibodies anti-PD-L1/CTLA-4, underscoring the utility of checkpoint inhibition in cancer immunotherapy (NCT03182816, NCT02873390, NCT02862028). This evidence concerns the gene CTLA4 and cancer.